24.52USD+5.87%Mkt Cap: 322.05M $P/E: —Today
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflo…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap322.05M $
Enterprise Value125.06M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.45M $
Revenue/Share—
Last Price24.52 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-88.91
EPS (TTM)-0.12
EPS (Forward)—
52W Range
18.8683% of range25.68
52W High25.68 USD
52W Low18.86 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE157.26%
ROA-212.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.11M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt585.05K $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.89
Current Ratio0.39
Quick Ratio0.11
Book Value/Sh-0.2660 USD
Cash/Share0.0480 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.91M
Float3.37M
Insiders5.06%
Institutions0.00%
Technical
SMA 5017.74 (+38.2%)
SMA 20017.74 (+38.2%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)576.84K
Avg Vol (10d)330.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—